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Background. The Duffy-null trait and ethnic netropenia are both highly prevalent in Africa. The influence of
pre-seroconversion levels of peripheral blood cell counts (PBCs) on the risk of acquiring human immunodeficiency
virus (HIV)–1 infection among Africans is unknown.
Methods. The triangular relationship among pre-seroconversion PBC counts, host genotypes, and risk of HIV
acquisition was determined in a prospective cohort of black South African high-risk female sex workers. Twenty-
seven women had seroconversion during follow-up, and 115 remained HIV negative for 2 years, despite engaging in
high-risk activity.
Results. Pre-seroconversion neutrophil counts in women who subsequently had seroconversion were
significantly lower, whereas platelet counts were higher, compared with those who remained HIV negative.
Comprising 27% of the cohort, subjects with pre-seroconversion neutrophil counts of ,2500 cells/mm3 had a 3-
fold greater risk of acquiring HIV infection. In a genome-wide association analyses, an African-specific
polymorphism (rs2814778) in the promoter of Duffy Antigen Receptor for Chemokines (DARC 246T . C) was
significantly associated with neutrophil counts (P 5 7.9 3 10211). DARC 246C/C results in loss of DARC
expression on erthyrocytes (Duffy-null) and resistance to Plasmodium vivax malaria, and in our cohort, only
subjects with this genotype had pre-seroconversion neutrophil counts of ,2500 cells/mm3. The risk of acquiring
HIV infection was3-fold greater in those with the trait of Duffy-null–associated low neutrophil counts, compared
with all other study participants.
Conclusions. Pre-seroconversion neutrophil and platelet counts influence risk of HIV infection. The trait of
Duffy-null–associated low neutrophil counts influences HIV susceptibility. Because of the high prevalence of this
trait among persons of African ancestry, it may contribute to the dynamics of the HIV epidemic in Africa.
The malarial parasite Plasmodium vivax requires Duffy
Antigen Chemokine Receptor (DARC) to gain entry
into red blood cells (RBCs) [1, 2]. In the homozygous
state, the DARC-null allele (due to the 246T . C
polymorphism in the DARC promoter) imparts selec-
tive loss of DARC expression on RBC (DARC- or Duffy-
null or -negative phenotype). Consequently, the
DARC246C/C genotype results in resistance to P. vivax
infection [1, 2]. Notably, the DARC-null allele is highly
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prevalent among Africans, and there is a compelling case for the
DARC locus to have been affected by selection [3]. However, the
impact of this selection on present-day infectious diseases re-
mains largely unknown.
Interestingly, there is a striking geographical overlap between
the prevalence of the DARC-null allele and human immunode-
ficiency virus (HIV) infection in Africa [4, 5]. In addition, DARC
is a binding protein for multiple chemokines, and RBC-DARC
regulates intravascular levels of pro-inflammatory chemokines
that influence HIV cell entry [6] and inflammation [1, 2, 7, 8].
Substantiating its possible role in inflammatory processes rele-
vant to HIV pathogenesis [9], RBC-DARC modifies chemokine
and coagulation responses following intravenous administration
of endotoxin to humans [10, 11]. Furthermore, HIV-1 adsorbs
to erythrocyte DARC [12, 13] and thence can be transferred to
CD41 target T cells [12], suggesting that RBCs might act as
carriers of infectious HIV-1 particles to susceptible cells.
Our original evaluation of the associations of DARC246C/C
with susceptibility to HIV/AIDS [12] conducted in a well-
established natural history cohort of HIV from the United
States revealed that, among HIV-infected African American
persons, the DARC-null phenotype associated with a survival
advantage. By contrast, DARC246C/C was associated with an
increased risk of acquiring HIV infection [12]. A mechanistic
model was envisaged whereby DARC impacted on HIV/AIDS
susceptibility by mediating trans-infection of HIV-1, affecting
chemokine-HIV interactions, and influencing chemokine-driven
inflammation [12].
However, the association ofDARC genotype with susceptibility
to HIV/AIDS was not observed by others [14–17] who regarded
this association as a false-positive result because of the methods
used for adjustment of population admixture between African
American HIV-infected patients versus HIV-uninfected control
subjects [15–17]. However, population stratification was unlikely
to explain our original results because the case patients and
control subjects were epidemiologically similar (eg, they were US
Air Force personnel), the genetic markers used to adjust for ad-
mixture predicted self-reported ethnicity with .98% accuracy
[12], and additional analyses with a validated panel of 96 ancestry
informative markers [18] revealed no evidence for population
stratification [19]. Also, genetic associations for even one of
the most intensively scrutinized HIV disease-retarding poly-
morphisms in the HIV field, namely the CCR5-D32 allele, ex-
hibits extensive heterogeneity across cohorts [20, 21]. Therefore,
in our riposte [19], we posited that differences between our and
others’ study end points and cohort characteristics [19] may have
accounted for the disparate associations and obscured complex
DARC genotype-phenotype relationships pertinent to HIV/AIDS.
Of special relevance was the demonstration that the
DARC-null state is a strong genetic basis for ethnic leucopenia
and/or neutropenia [22, 23], a hematologic condition observed
commonly in persons of African descent [24–26]. We therefore
evaluated whether there is a triangular relationship among the
DARC-null state, leucopenia, and HIV disease course [27].
These analyses demonstrated that during HIV infection,
DARC246C/C genotype associated with a survival advantage
but mainly in a specific cellular context defined by a low WBC/
neutrophil count [27].
For these reasons, we hypothesized that there was a similar
triangular relationship amongDARC-null, low neutrophil levels,
and HIV susceptibility. However, the high occurrence of
leukopenia and neutropenia during HIV infection [27, 28]
precluded a cross-sectional analysis of leukocyte levels in HIV-
infected versus HIV-uninfected subjects as a means to
investigate whether pre-infection peripheral blood cell (PBC)
counts influenced the future risk of acquiring HIV infection. For
these reasons, we investigated a prospective cohort of high-risk
women (HRW), the majority of whom (80%) were sex workers
(SWs) from South Africa [29]. During the intensive prospective
follow-up period of 2 years, 19% of the evaluable HRW/SWs
had seroconversion, whereas the other subjects remained un-
infected despite high-risk activity. These epidemiological char-
acteristics made this cohort ideal for evaluating the proposed
triangular relationship amongDARC-null, low neutrophil levels,
and HIV susceptibility. Our results affirmed this relationship.
METHODS
Study Cohort
We evaluated a cohort of 245 black HRW/SWs (Figure 1A) from
South Africa who were part of the CAPRISA 002 acute infection
study [29]. Of these subjects, 27 HRW/SWs had seroconversion
during prospective follow-up, and 115 participants remained
HIV negative for 2 years and comprised the study group in-
vestigated here.
Genetic Analyses
Genetic data were obtained from a genome-wide association
study (GWAS) using the Human Duo-1M Illumina beadchip
according to the Infinium HD protocol. Of the 1,144,696
markers typed, 874,956 markers passed quality control (see
Supplementary Methods) and were used for final analyses.
Statistical Analyses
We used baseline (initial) values of the PBC (ie, RBC, platelet,
and white blood cell [WBC] counts) or the main components of
WBC as predictors of subsequent HIV acquisition risk, where
‘‘baseline’’ refers to values obtained when all subjects were HIV
seronegative at cohort entry. These associations were in-
vestigated using multivariate unconditional logistic regression
models. The normal range for neutrophils in healthy persons is
2500–6000 cells/mm3 [30], and we used the lower end of this












threshold (2500 cells/mm3) as a cutoff in some of the statistical
analyses.
Methods for adjustment of population admixture using 3160
ancestry informative markers (Supplementary Tables 1 and 2)
are described in the Supplementary Methods. In brief, from
these ancestry informative markers we derived and compared
the values of the top 10 principal components (PCs) obtained by
EIGENSTRAT analysis [31] between HIV-infected and HIV-
uninfected subjects. We then adjusted the multivariate models
for the scores for the top 10 PCs and excluded subjects who were
classified as outliers (n 5 4) (see Supplementary Methods for
details).
Using PLINK software [32], we determined the association of
each polymorphism with the quantitative hematological traits
(neutrophil and platelet counts; see Results) by using the as-
ymptotic Wald test. We also conducted the GWAS analyses
using multivariate linear regression models by adjusting for the
top 10 PCs.
RESULTS
PBC Counts and Risk of HIV Infection
Evaluation of the association of the baseline (preinfection) val-
ues of the 3 major PBCs—namely WBC, RBC, and platelet
counts—revealed that a higher baseline WBC count was asso-
ciated with a reduced risk of acquiring HIV infection (Table 1).
Specifically, each 1000-cell/mm3 increment in the baseline WBC
count was associated with a 28% reduction in the risk of sub-
sequently acquiring HIV (odds ratio [OR], 0.72; 95% confidence
interval [CI], 0.55–0.93). By contrast, an initial high platelet
count was associated with an increased future risk of acquiring
HIV infection, with each additional 100,000-cell/mm3 in-
crement in the platelet count associating with a 2 fold in-
creased risk of HIV infection (Table 1). A significant association
between RBC count and HIV risk was not detected (Table 1).
To determine which specific leukocyte subset contributed to
the association observed for the WBC count, we replaced the
baseline WBC count in the multivariate logistic regression
model with the baseline counts of its major components (eg,
neutrophil and lymphocyte counts). This model revealed that
each 1000-cell/mm3 increase in the baseline neutrophil count
was associated with a 36% lower risk of subsequently acquiring
HIV infection (OR, 0.64; 95% CI, 0.45–0.94; Table 2, model 1).
An association between the baseline values of other WBC
components was not detected (Table 2, model 1). In a backward
elimination stepwise regression model, the only 2 PBCs that
remained statistically significant were platelet and neutrophil
counts (Table 2, model 2). In the multivariate logistic regression
models, when we replaced the baseline lymphocyte count with
baseline counts for CD41 or CD81 T cells, only neutrophil and
A B
Figure 1. Study subjects and principal component analyses for
population stratification. A, Study subjects. CAPRISA 002 Acute Infection
Study screened 775 high risk women from Durban, KwaZulu-Natal, South
Africa, who self-identified as sex workers or who reported .3 sexual
partners in the prior 3 months [29]. Four hundred sixty-two of these were
human immunodeficiency virus (HIV)–positive subjects ,and 68 met
exclusion criteria as described previously (e.g. pregnant, declined follow-
up for 2 years) [29]. Two hundred forty-five subjects (green box) were
enrolled in the Acute Infection study [29]. Thirty were excluded for the
present study because they were either not black or DNA was
unavailable. Of the 215 HIV-negative women who were observed
prospectively, 169 (78.6%) were self-reported sex workers, and at the end
of the 2-year follow-up period, 28 women had experienced seroconvesion
and 122 remained HIV seronegative (exposed uninfected). 65 women who
had less than 2 years of follow-up were excluded from the current
analyses. Baseline peripheral blood cell and GWAS data were available
on 27 HIV-seroconverting women and 115 HIV nonseroconverting women.
The sexual risk behavior and other characteristics of these study subjects
were similar to those as described previously [29]. B, Evaluation of
population stratification in the study groups. Red squares and blue
diamonds indicate the mean principal component (PC) scores for the top
10 PCs for HIV-infected and -uninfected subjects, respectively. Error bars
represent the 95% confidence interval. Numbers at the right side are
significance values obtained using the Student t test.
Table 1. Association of Major Peripheral Blood Cell (PBC)
Components With Future Risk of Acquiring Human Immunodefi-
ciency Virus (HIV) Infection
PBC
All subjects Excluding outliers
OR 95% CI P OR 95% CI P
RBC count 1.08 .29–3.95 .911 1.19 .30–4.76 .801
Platelet count 2.31 1.31–4.08 .006 2.61 1.38–4.93 .003
WBC count 0.72 .55–.93 .014 0.68 .51–.91 .009
NOTE. Unconditional multivariate logistic regression modeling using
baseline PBC values from 142 individuals; outliers are as described in the
methods section. An odds ratio (OR) that is .1 or ,1 indicates that a higher
value of the hematological parameter is associated with a higher or lower risk
of acquiring HIV infection, respectively. ORs are per 106 RBCs, per 105
platelets, or per 103 WBCs (all in cells/mm3). CI, confidence interval; RBC, red
blood cell; WBC, white blood cell.












platelet counts were retained in the final models (data not
shown).
These associations were unlikely to be due to differences in
population admixture of the HIV-infected versus HIV-nega-
tive HRW. First, none of the mean scores for the top 10 PCs
for HIV-positive and HIV-negative groups differed signifi-
cantly (Figure 1B). Second, the associations for neutrophil
and platelet counts observed in the final model of the stepwise
regression for PBCs shown in Table 2 (model 2) remained
unchanged after inclusion of the top 10 PCs as covariates
in this regression model (Table 2, model 3). Third, all the
aforementioned associations remained unchanged when we
excluded from the multivariate model subjects who were
classified as outliers (Table 2).
Normal ranges of blood differential counts vary depending
on age, sex, population group, and other factors, and there are
inter-laboratory differences in reference intervals. Nonetheless,
2500 cells/mm3 is widely used as the lower limit of normal
neutrophil counts [30], and a neutrophil count ,1500 cells/
mm3 has become the commonly accepted definition of neu-
tropenia [25]. With these general guidelines in mind, we de-
termined the threshold of baseline neutrophil counts below
which future risk of HIV infection increased (Figure 2A).
Approximately 31% of the HRW with a baseline neutrophil
count of ,1500 or 1500–2500 cells/mm3 subsequently had
seroconversion, whereas only 15% of those with a neu-
trophils count .2500 cells/mm3 did so (Figure 2A). By logistic
regression analyses, in addition to platelet counts, an initial
neutrophil count of ,2500 cells/mm3 was associated with a
3-fold greater future risk of subsequently acquiring HIV infection
before or after adjusting for population admixture (Figure 2B).
Thus, in our study population, an initial neutrophil count of
2500 cells/mm3 reflected a threshold for altered HIV risk.
Genome-wide Association for Neutrophil and Platelet Counts
Because of the observed associations of neutrophil and platelet
counts with risk of HIV, we used a GWAS approach to identify
polymorphisms that may associate with variability in these 2
traits. GWAS for neutrophil counts revealed only 1 genetic
marker, rs2814778 on chromosome 1, that associated signifi-
cantly with neutrophil counts, and it represents the T-46C
polymorphism in DARC (P 5 1.4 3 1028) (Figure 3A, Sup-
plementary Figures 1–3 and Supplementary Table 3). Even after
removal of subjects classified as outliers and adjusting for the top
10 PCs, the association of the DARC polymorphism with neu-
trophil counts remained highly significant (P 5 7.9 3 10211)
(Figure 3B). Furthermore, the strong association between
rs2814778 and neutrophil counts is unlikely to have been in-
flated due to potential systematic errors (eg, population ad-
mixture) as suggested by Q-Q plots analysis (Figure 3C).
Moreover, this DARC polymorphism explained 26% (R2 by
univariate model) of variability in neutrophil counts. An asso-
ciation for platelet counts that met the genome-wide level for
Table 2. Association of Peripheral Blood Cell (PBC) Counts and
White Blood Cell Components With Future Risk of Acquiring
Human Immunodeficiency Virus (HIV) Infection
All subjects Excluding outliers
PBC OR 95% CI P OR 95% CI P
Model 1: baseline (pre-seroconversion) cell counts at study entry
RBCs 1.11 .27–4.54 .887 1.19 .27–5.31 .817
Platelets 2.48 1.42–4.33 .004 2.77 1.44–5.35 .002
Neutrophils 0.64 .45–.94 .021 0.62 .42–.93 .022
Lymphocytes 0.61 .28–1.33 .217 0.58 .25–1.32 .194
Monocytes 1.28 .89–1.89 .212 1.18 .78–1.81 .429
Eosinophils 2.01 .25–16.2 .511 1.91 .22–16.9 .560
Basophils 0.89 .74–1.07 .209 0.91 .75–1.06 .345
Model 2: Final model from backward stepwise regression
Platelets 2.15 1.22–3.80 .008 2.40 1.31–4.40 .004
Neutrophils 0.69 .50–.95 .024 0.65 .46–.92 .016
Model 3: Model 2 adjusted for PC1–PC10 from EIGENSTRAT
Platelets 2.73 1.44–5.17 .002 2.90 1.48–5.69 .002
Neutrophils 0.64 .46–.90 .011 0.58 .39–.86 .006
NOTE. An odds ratio (OR) that is .1 or ,1 indicates that a higher value of
the hematological parameter is associated with a higher or lower risk of
acquiring HIV infection, respectively). ORs are per 106 RBCs, per 105 platelets,
per 103 neutrophils or lymphocytes, per 100 monocytes, and per 10 basophils
(all in cells/mm3). Model 1, full unconditional multivariate logisitc regression
model. Model 2, backward elimination stepwise regression model with
a probability retention criterion of 0.1. Model 3, final model after adjustment
for top 10 principal components from EIGENSTRAT. CI, confidence interval.
A B
Figure 2. Association of the initial or baseline neutrophil and platelet
counts with risk of acquiring human immunodeficiency virus (HIV)
infection. A, Proportion of HIV-positive and HIV-negative subjects in the
indicated categories of baseline neutrophil counts. B,Multivariate logistic
regression analyses for the association of platelet counts and low
neutrophil counts (defined as ,2500 neutrophils/mm3) before (blue) and
after (red) adjustment for potential population stratification of the top 10
principal component (PC) scores. Adjustment was done by including the
top 10 PCs as covariates in the logistic regression model. Numbers at the
top are the significance values. The reference group for neutrophil counts
was the category of>2500 cells/mm3. Platelet count was included in the
model as a continuous variable of increments of 100,000 cells/mm3.












statistical significance was not detected (Supplementary Figure 4
and Supplementary Table 4).
DARC 246C/C, Neutrophil Counts and Risk of HIV
We next investigated whether HIV risk might differ according to
the initial neutrophil count. Consistent with the GWAS findings,
DARC-negative subjects had significantly lower neutrophil
counts than DARC-positive individuals (Table 3). Although the
leukopenia associated with the DARC246C/C is attributable
mainly to low neutrophil counts [22, 23], subjects with this
genotype also had lower monocyte counts (Table 3).
The cumulative distributions of neutrophil counts in DARC-
negative and DARC-positive subjects were significantly different
(Figure 4A). None of the 50 DARC-positive subjects had
a baseline neutrophil count,2500 cells/mm3 (Figure 4A). These
low neutrophil counts were found only in DARC-negative
subjects, and those DARC-negative subjects with a low neu-
trophil count comprised nearly 27% of the entire cohort (Figure
4B). Notably, a neutrophil count of 2500 cells/mm3 is the same
neutrophil threshold that is associated with altered risk of HIV
(compare Figures 4B and 2A). Predictably, compared with all
other subjects, the DARC-negative subjects with a baseline
neutrophil count of,2500 cells/mm3 had a 2.6-fold higher risk
of acquiring HIV infection (OR, 2.61; 95% CI, 1.09–6.24;
P 5 .028), resulting in an overrepresentation of those with the
‘‘DARC-negative-low baseline neutrophil’’ genotype-phenotype
Figure 3. GWAS for the traits of neutrophil counts. Manhattan plots indicate the -log10 P value of the association statistic plotted by the chromosomal
location of the marker (x-axis). Chromosome numbers are shown at the top. Red arrows indicate the marker with strongest association that was
statistically significant at the genome-wide significance threshold level of 5.83 1028. A, Significance value based on the Wald statistic for all subjects.
B, Analyses after removing 4 subjects who were classified as outliers. The significance values obtained after adjustment for the top 10 principal
components derived from the 3073 ancestry informative markers is also shown. C, Q-Q plot analysis. We generated a Q–Q plot of observed versus
expected P values for the association of neutrophil counts. P-values are transformed using the inverse v2 distribution with 1 degree of freedom. Scatter of
dots close to the diagonal line indicate negligible likelihood of population admixture. The single point at the top (highlighted using red arrow) represents
the association of rs2814778 with neutrophil count. Estimated k genomic inflation factor is shown, indicating whether systematic biases, such as
population stratification, are present [33]. In this case, k 5 1.0045, suggested negligible overall effect of stratification or other systematic biases.












relationship among subjects who had seroconversion,
contrasting with an underrepresentation of this genotype-
phenotype correlate among those who remained HIV negative
(Figure 4C). In addition, those with DARC-negative-associated
low baseline neutrophil counts seroconverted 2.4 times faster
than all other subjects (Figure 4D).
Ideally, the comparator group for DARC-negative subjects
with neutrophil counts ,2500 cells/mm3 would be DARC-
positive subjects with neutrophil counts ,2500 cells/mm3.
However, no such individuals were present in our study pop-
ulation. To capitalize on the entire range of baseline neutrophil
counts, we used an alternative statistical approach in which the
DARC-negative-associated low neutrophil count is considered
as an inherited trait, and a higher probability of possessing this
trait is conceptualized as being associated with a higher risk of
acquiring HIV infection (see Supplementary Methods). We es-
timated the probability of possessing the DARC246C/C geno-
type for a given neutrophil count and then used receiver
operating characteristic curve to determine the cutoff value
above which the probability of possessing this trait increased the
likelihood of acquiring HIV infection (Supplementary Figure 5).
These analyses revealed that a high probability for this trait as-
sociated with a nearly 3-fold increased risk and rate of acquiring
HIV infection (Supplementary Table 5).
DISCUSSION
Investigation of a well-characterized prospective cohort of high-
risk black South African women revealed several major findings.
Preinfection high platelet and low WBC counts, attributable
mainly to low neutrophil counts, were associated with increased
future HIV acquisition risk. The association of platelet counts
with HIV risk may relate to platelets serving as an interface
between coagulation and inflammation or immunity [34, 35].
Neutrophils, by serving as first defenders against infections, may
play a critical role in instructing the adaptive immune responses
relevant to HIV pathogenesis (reviewed in [36, 37]). Further-
more, low neutrophil counts in persons of African ancestry are
associated with higher levels of interleukin (IL)–8 and gran-
ulocyte colony-stimulating factor [38]: both biomarkers corre-
late with inflammation [38, 39] and IL-8 increases HIV-1
transmission ex vivo [40]. Thus, low neutrophil counts, by al-
tering the inflammatory milieu, may influence HIV risk. As
a corollary to our findings, high neutrophil counts associate
with resistance to acquiring HIV in high-risk men in the
MACS cohort [41].
Interestingly, GWAS analyses demonstrated that possession of
the DARC-null allele is highly predictive of low neutrophil
counts. This finding is consistent with an extensive admixture
mapping study that demonstrated that the DARC246T/C
polymorphism is significantly more predictive of neutrophil
count than of ancestry and that the DARC-null allele was causal
for low neutrophil counts in persons of African descent [23]. In
our study participants, only DARC-null subjects had pre-
infection neutrophil counts ,2500 cells/mm3. The association
of DARC246C/C with ethnic leukopenia/neutropenia may re-
late to DARC’s chemokine-binding and/or transport function,
impacting the levels of chemokines that influence neutrophil
trafficking [1, 2, 7].
In addition, we found the increased HIV risk associated with
the DARC-null state is mainly in those with a low neutrophil
count; such subjects constituted 27% of our study population.
The trait of DARC-null-associated low neutrophil counts asso-
ciated with a3-fold higher risk and3-fold accelerated rate of
acquiring HIV. Given the high prevalence of this unfavorable
genotypic hematological determinant among persons of African
ancestry, this trait may contribute to the HIV epidemic in Africa.
Although the biological mechanism for the trait of DARC-
null-associated low neutrophil counts remains unknown, it is
noteworthy that leukopenia/neutropenia is the usual response to




No. of subjects Mean 6 SE No. of subjects Mean6 SE
RBC count, 3 106 cells/mm3 50 4.32 60.05 92 4.37 60.038 .453
Platelet count, 3 105 platelets/mm3 50 3.22 60.11 92 3.02 60.88 .179
WBC count, 3 103 cells/mm3 50 7.99 60.27 92 5.90 60.19 ,.001
Neutrophil count, 3 103 cells/mm3 50 5.01 60.21 92 3.03 60.17 ,.001
Lymphocyte count, 3 103 cells/mm3 50 2.25 60.09 92 2.23 60.07 .807
Monocyte count, 3 102 cells/mm3 50 0.46 60.02 92 0.36 60.01 ,.001
Eosinophil count, 3 102 cells/mm3 50 0.20 60.02 92 0.26 60.03 .386
Basophil count, 3 10 cells/mm3 50 0.06 60.01 92 0.05 60.003 .273
NOTE. RBC, red blood cell; SE, standard error; WBC, white blood cell.
a Mean values of initial pre-seroconversion hematological parameters in HRW/CSWs possessing the DARC 246C/C genotype (DARC2 on RBC) compared with
those lacking this genotype (DARC1 on RBC).












malarial infection, whereas higher WBC and/or neutrophil
counts associate with parasite density and severe disease [42, 43].
In addition, early neutrophil depletion prevents experimental
cerebral malaria [44], suggesting that high neutrophil counts
may contribute negatively to aspects of malaria pathogenesis.
Thus, from an evolutionary perspective, 2 phenotypic traits as-
sociated with the DARC-null state, namely resistance against
parasite entry and low neutrophil counts, may have been se-
lected for because together they may have afforded protection
against an ancestral malarial infection [3]. However, reflecting
an evolutionary trade-off, the ancestral beneficial impact of
DARC-null in the present-day era of HIV/AIDS emergence is
offset by its detrimental association with an increased HIV ac-
quisition risk. Notably, double-edged genotype-phenotype re-
lationships have also been described for the HIV resistance
CCR5-D32 allele, which affords protection against HIV but
susceptibility with other infectious agents, such as West Nile
virus [45].
It is important to note that because of the close association of
Duffy-null with low neutrophil counts in our study population,
it is difficult to ascribe an independent effect of low neutrophil
counts or the DARC-null state on HIV risk. Hence, these 2 host
factors may act independently or as a conjoint genetic-cellular
determinant of HIV susceptibility. Nonetheless, together with
prior results [12, 27], these findings underscore the extant in-
tricate triangular relationship among DARC-null state, low
neutrophil counts, and susceptibility to HIV/AIDS. Conse-
quently, depending on the cohort analyzed, failure to account
for this intricate relationship as well as inter-cohort differences
in prevalence of the trait of DARC-null-associated low neutro-
phil counts may obscure the ability to discern true associations
of DARC-46C/C with susceptibility to HIV/AIDS.
Our study has limitations. The sample size was small, and we
could not account for the effect of intercurrent sexually trans-
mitted infections on HIV acquisition risk. In addition, it is
difficult to document the degree of exposure to HIV prior to or
after cohort entry—that is, we cannot distinguish whether those
who remained HIV negative, despite high-risk activity, did so
because of genetically-mediated resistance to HIV or limited
exposure to HIV. Notwithstanding these limitations, as noted
above and reported previously [29], the cohort we evaluated has
many strengths that tend to offset these shortcomings. The study
participants were recruited after screening a large number (n 5
775) of HRW with a much higher prevalence of HIV infection
(60%) than the prevalence rates of HIV among other South
African women [29]. Thus, this cohort, despite its small size,
favors the identification of host factors with strong effects on
HIV susceptibility. In addition, the prevalence of the DARC-null
allele is not fixed among South Africans, allowing comparisons
of DARC-positive and DARC-negative subjects.
Given the high prevalence of the Duffy-null state in Africans, it
is conceivable that this genetic state could modify the population
dynamics of the HIV epidemic in Africa by 2 means. First, by
serving as a causal mechanism for low neutrophil counts, the
DARC-null trait associates with an increased HIV acquisition
risk. Second, by imparting a survival advantage to leukopenic
HIV-infected subjects [12, 27], it prolongs the infectious state.
Together, these 2 effects would lead to increased HIV prevalence
within the population, facilitating continued HIV transmission
from a larger pool of infected individuals for a longer period of
time. It is well known that viruses have evolved means for sub-
verting or exploiting the immune system to coexist with their
hosts [46, 47]. Thus, the targeting by HIV of the null state for the
chemokine-binding protein DARC may impart a selective ad-
vantage for the virus, akin to the effects of targeting the che-
mokine system by other viral pathogens [46, 47].
Figure 4. Association of DARC 246C/C–associated low neutrophil
counts with risk and rate of acquiring human immunodeficiency virus (HIV)
infection. A, Cumulative frequency distribution of neutrophil counts based
on whether subjects were DARC negative or DARC positive and had
a baseline neutrophil count of <2500 or .2500 cells/mm3. The number
of subjects in each of the 4 possible DARC genotype-neutorphil groups is
shown and color-coded to match the frequency plots. B, Proportion of HIV-
positive and HIV-negative subjects according to DARC genotype and
baseline neutrophil counts of <2500 or .2500 cells/mm3. C, Prevalence
of DARC-negative-low neutrophil (red), DARC-negative-high neutrophil
(green), and DARC-positive subjects (blue) phenotypes at enrollment (time
0 day), and 2 years after enrollment. D, Kaplan-Meier plots for time to HIV
diagnosis from enrollment into the cohort for the same 3 color coded
groups shown in panel A. RH, relative hazard, CI, confidence interval; P,
significance values derived by Cox proportional hazard models. In model
1, the reference (RH5 1) for the Cox models are DARC-positive subjects.
In model 2, comparison of persons with DARC-negative-low baseline
neutrophil versus all other subjects (RH 5 1).
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